PFE
NYSEPfizer Inc.
Basic Materials · Pharmaceutical Preparations
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$81.3B
2021
$101.2B
2022
$59.6B
2023
$63.6B
2024
$62.6B
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$62.6B
Net Income$7.8B
Gross Profit—
Oper Income—
EPS (dil)$1.36
Rev/sh$10.98
FCF/sh$1.59
Book/sh$15.23
Gross M—
Oper M—
Profit M12.5%
FCF M14.5%
ROE9.0%
ROA3.8%
ROIC—
R&D/Rev—
Rev Y/Y-1.6%
Rev 3Y CAGR-14.8%
EPS Y/Y-3.5%
EPS 3Y CAGR-37.1%
FCF 3Y CAGR-29.6%
Payout—
Div/sh$1.72
Shs Chg Y/Y+0.2%
Current Ratio1.16
Quick Ratio0.87
Debt/Eq0.75
Int Coverage—
Net Debt$63.6B
Total Debt$64.8B
Cash & Eq$1.2B
Total Assets$208.2B
Oper CF$11.7B
Capex$2.6B
Free CF$9.1B
Buybacks$0
Equity$86.8B
Liabilities$121.4B
Shs Outstand5.70B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $81.3B | $101.2B | $59.6B | $63.6B | $62.6B |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | $22.0B | $31.4B | $2.2B | $8.1B | $7.8B |
| Diluted EPS | $3.85 | $5.47 | $0.37 | $1.41 | $1.36 |
| Operating Cash Flow | $32.9B | $29.3B | $8.7B | $12.7B | $11.7B |
| Free Cash Flow | $30.2B | $26.0B | $4.8B | $9.8B | $9.1B |
COMMUNITY · $PFE0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.